With successful findings from a phase 3 trial of its bevacizumab biosimilar candidate, Iranian company AryoGen Pharmed is a step closer to commercialization of this product.
The importance of biosimilars worldwide is illustrated by the development of biosimilar manufacturing and development beyond the United States and Europe. In Iran, AryoGen Pharmed has a growing portfolio of biosimilars and aims to become a leader in the development of these medicines. Well established as a biopharmaceutical manufacturing center, AryoGen Pharmed has received a Good Manufacturing Practice certificate from the Europeans Medicines Agency.
Investigators described successful findings for the company’s bevacizumab biosimilar candidate, BE1040V, in a recent phase 3 clinical study in Clinical Therapeutics. The authors outline the product's potential value as a treatment for metastatic colorectal cancer (mCRC).
Biologics Improve mCRC Survival
They note that 5-year survival for patients with this disease is low at just 14%. However, overall survival with systemic chemotherapy in clinical trials has risen to 30 months from 11 months, and these gains have been aided by the introduction of newer chemotherapeutic agents, such as oxaliplatin and irinotecan, in combination with combination regimens such as fluorouracil and biologic agents.
“In fact,” the authors write, “only trials that have incorporated the use of biologic agents into regimens of combination therapies have consistently reported a median survival rate of over 24 months.”
Bevacizimab is one of the biologic agents that have been employed with success in the mCRC setting. The drug works by inhibiting vascular endothelial growth factor-A, which helps in the formation of blood vessels that are essential to the growth of tumors.
A biosimilar bevacizumab such as BE1040V can play an important role in making these advanced therapeutic combinations available to patients, the authors note. Biosimilars are highly similar to innovator brands and have no clinically significant differences with regard to tolerability and efficacy. The chief advantage of a biosimilar over an innovator product is its presumed greater affordability for patients and health care systems.
“Due to the considerable cost of the reference product bevacizumab and also the high mortality rate of mCRC in Iran, BE1040v was developed as a biosimilar of the reference product bevacizumab,” investigators wrote.
The just-published study demonstrated that the candidate bevacizumab biologic was noninferior to the reference product in terms of efficacy and tolerability.
For a full discussion of the study findings, visit AJMC.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.